On October 23, 2025, the Food and Drug Administration approved belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who
Similar Posts
YoCrunch® Products Voluntarily Recalled by Danone U.S. Due to Potential Presence of Plastic Pieces in Dome Topper
Danone U.S. is voluntarily recalling YoCrunch® products sold at retail stores nationwide due to the potential presence of plastic pieces in the dome topper. If consumed, the plastic pieces could potentially cause a choking response. The issue is isolated only to the separately packaged topper and doForce Forever may be harmful due to hidden drug ingredients
Consumers should not to purchase or use Force Forever, a product promoted and sold for joint painInnoStar Bio-Tech Nantong Company, Ltd – 11/1/2024
InnoStar Bio-Tech Nantong Company, Ltd – 11/1/2024. Country: United States. Record Type: Response to Form 483Ongoing | Non-malignant Hematological, Neurological, and Other Disorder Indications Accelerated Approvals
Drug and Biologic Accelerated Approvals Based on a Surrogate EndpointRecommendations for Complying With Over-the-Counter Monograph Procedure for Minor Changes C001: Minor Changes to Solid Oral Dosage Forms for Certain Over-the-Counter Monograph Drugs
This guidance provides recommendations for how requestors can comply with the requirements described in the Proposed Administrative Order titled Over-the-Counter Monograph Procedure for Minor Changes C001: Minor Changes to Solid Oral Dosage Forms for Certain Over-the-Counter Monograph Drugs.Brands International Corporation – 06/21/2024
Brands International Corporation – 06/21/2024. Country: Canada. Record Type: 483